CHINA PHARMA HOLDINGS, INC. (CPHI): Nasdaq/NYSE listing notice — China Pharma receives NYSE American deficiency notice for equity shortfall

CHINA PHARMA HOLDINGS, INC.

Stockholders' equity of $2.8M as of Sept 30, 2022 below the $4.0M minimum required by Section 1003(a)(ii).
Company has reported net losses in four most recent fiscal years ended Dec 31, 2021.
Must regain compliance with equity standard by Dec 15, 2023, and price noncompliance by March 26, 2023.
NYSE American accepted a plan on Aug 29, 2022 to cure equity noncompliance; failure to progress may trigger delisting.
Common stock (CPHI) continues trading with .BC indicator while company attempts to cure deficiencies.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

CHINA PHARMA HOLDINGS, INC. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(ii)).

Exchange: nyse american
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 1003(a)(ii)

Exact text from the filing

if it has reported losses from continuing operations and/or net losses in its four most recent fiscal years. The Deficiency Letter noted that Company had stockholders’ equity of $2.8 million as of September 30, 2022, and has reported losses from continuing operations and/or net losses in its four most recent fiscal years ended December 31, 2021. The Company remains

View on SEC.gov

Browse all listing & compliance notices →

CHINA PHARMA HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-22-077304

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.